Market Trends of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Industry
This section covers the major market trends shaping the Acute Bacterial Skin & Skin Structure Infection Market according to our research experts:
Hospital-acquired ABSSI is Expected to Hold Significant Market Share During the Forecast Period
Infections acquired in a healthcare setting are known as hospital-associated infections (HCAIs). They may cause (or prolong) stays in acute care hospitals, increase medical and economic burdens, and cause morbidity and mortality. According to a study published in the Journal of Antimicrobial Chemotherapy in November 2021, adult inpatients in the National Health Service hospitals in England have 834,000 hospital-acquired infections (HCAIs) each year, accounting for 7.1 million occupied hospital bed days (21% of total annual bed days) and a EUR 2.7 billion (USD 2.8 billion) economic burden. Such a huge burden of hospital-acquired infections is expected to drive the segment's growth due to the rising adoption of ABSSSI therapies for these infections.
According to the same source, the prevalence of HCAI is estimated to be 6.0%. The most common infections were skin and soft tissue infections (SSTIs), which included surgical site infections (SSIs). Patients in intensive care units had the highest rate of hospital-acquired ABSSSI. Thus, growing prevalence of hospital-acquired infection is expected to boost the segment.
According to a study published in the International Journal of Antimicrobial Agents in August 2022, almost 10% of all hospital admissions in the United States and around 15% of all infections treated in European hospitals are due to ABSSSIs. Such a huge prevalence of hospital-based ABSSSI is expected to drive the segment due to the increased adoption of treatments for ABSSSI.
Therefore, as the high burden of hospital-acquired ABSSSI is expected to drive the market over the forecast period
North America Holds a Significant Share in the Market and is Expected to Continue the Same During the Forecast Period
North America may continue to hold a significant share in the acute bacterial skin and skin structure infection market during the forecast period due to extensive R&D activity, R&D spending, product pipeline, and novel product launches.
The growing product pipeline and product approval by regulatory authorities are expected to boost the market over the forecast period. For instance, in July 2021, the US FDA approved AbbVie's DALVANCE (dalbavancin) to treat acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth. DALVANCE is a single dose option administered as a 30-minute intravenous (IV) infusion for the treatment of ABSSSI caused by designated susceptible Gram-positive bacteria in pediatric patients, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Such launches are expected to drive the market in the region.
In January 2022, Paladin Labs Inc., a subsidiary of Endo International PLC, launched Xydalba (dalbavancin for injection), a 30-minute intravenous (IV) therapy in Canada for acute bacterial skin and skin structure infections (ABSSSI) that can be administered as a single- or two-dose regimen.
Thus, all such factors are expected to boost the market in North America over the forecast period.
